Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.64 USD | +1.15% | +10.46% | -63.13% |
Mar. 28 | CASI Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Mar. 05 | Top Midday Gainers | MT |
Financials (USD)
Sales 2024 * | 59.17M | Sales 2025 * | 88.09M | Capitalization | 34.29M |
---|---|---|---|---|---|
Net income 2024 * | - | Net income 2025 * | 11M | EV / Sales 2024 * | 0.58 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 0.39 x |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
7.76
x | Employees | 176 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 50.99% |
1 day | +1.15% | ||
1 week | +10.46% | ||
Current month | +12.15% | ||
1 month | -15.11% | ||
3 months | -57.83% | ||
6 months | -35.61% | ||
Current year | -63.13% |
Managers | Title | Age | Since |
---|---|---|---|
Wei Wu He
CEO | Chief Executive Officer | 59 | 19-04-01 |
Wei Zhang
DFI | Director of Finance/CFO | 64 | 18-08-31 |
Chun Hua Wang
COO | Chief Operating Officer | 52 | 16-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Wei Wu He
CEO | Chief Executive Officer | 59 | 19-04-01 |
Yue Wu
BRD | Director/Board Member | 62 | 13-03-31 |
Zhen Bo Su
BRD | Director/Board Member | 48 | 23-03-20 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-08 | 2.64 | +1.15% | 2,988 |
24-05-07 | 2.61 | -5.09% | 2,409 |
24-05-06 | 2.75 | -1.61% | 9,568 |
24-05-03 | 2.795 | +4.29% | 9,536 |
24-05-02 | 2.68 | +12.13% | 14,627 |
Delayed Quote Nasdaq, May 08, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-63.13% | 33.9M | |
+32.95% | 700B | |
+26.51% | 569B | |
-4.97% | 358B | |
+18.83% | 330B | |
+3.54% | 287B | |
+15.70% | 236B | |
+6.68% | 202B | |
-9.08% | 197B | |
+6.70% | 161B |
- Stock Market
- Equities
- CASI Stock